Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**L3MBTL histone methyl-lysine binding protein 4 (L3MBTL4)** is a nuclear protein involved in chromatin organization and the negative regulation of DNA-templated transcription. It is considered a member of the Polycomb group (PcG) proteins, which are important for maintaining genes in a repressed state through chromatin modification. The gene encodes a protein of approximately 623 amino acids and is conserved across several species. L3MBTL4 has been proposed as a tumor suppressor on chromosome 18p, with gene deletion, mutation, or downregulation implicated in some cancers. It does not have known direct interacting drugs or established biomarker roles, and there are no notable safety or therapeutic concerns currently associated with direct targeting of this molecule[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L3MBTL histone methyl-lysine binding protein 4 (L3MBTL4).